Zhengwei Zhu

BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts.

Decheng Capital LLC is a venture capital firm founded by Min Cui in 2011 having headquartered at Shanghai, China.

HHLR Management Pte Ltd. (HHLR) is an alternative investment management firm headquartered in Singapore. The firm is a subsidiary of Hillhouse Capital Group Ltd. in Hong Kong. Formerly known as Hillhouse Capital Management Pte Ltd., HHLR provides investment solutions to institutional investors as well as to non-profit foundations.

Octagon Capital Advisors LP (Octagon) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Ting Jia in 2019. Octagon provides discretionary investment advisory services to master-feeder, mini-master feeder, and Delaware series trust structures comprised of affiliated pooled investment vehicles.

Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation.

Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients.

Octagon Capital Advisor/ Private Equity (Octagon Capital) is a private equity subsidiary of Octagon Capital Advisors LP founded in 2019 by Ting Jia. The firm is headquartered in New York.

UGenix Biotech Ltd. is a holding company, which engages in the provision of prenatal testing, precision oncology, and pathogenic detection services. The company was founded on October 26, 2021 and is headquartered in Hong Kong.